Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
|
|
- Amanda Miles
- 6 years ago
- Views:
Transcription
1 Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine
2 Faculty Disclosure Consulting or Advisory Role: Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche Speakers' Bureau: Boehringer Ingelheim Research Funding: AstraZeneca 2
3 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 3
4 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 4
5 The Family of EGFR TKIs Wild-type EGFR Intrinsic mutant EGFR ErbB heterodimers (eg, Her2: ErbB3) Acquired T790M EGFR K K K K K K K Erlotinib Gefitinib 1st-generation TKI EGFR inhibition Activity range Reversible binding to wild-type and mutant EGFR Inactive on T790M mutant Afatinib Dacomitinib 2nd-generation TKI ErbB Family blockade Activity range Irreversible covalent binding to EGFR, ErbB2 and ErbB4 to inhibit all ErbB Family signalling Broader activity to overcome EGFR TKI resistant mutations Osimertinib 3rd-generation TKI EGFR mutant specific inhibitor Activity Specificity for EGFR T790M mutant; EGFR wild-type sparing Irreversible covalent binding to mutant EGFR Range K Kinase domain Liao et al. Curr Opin Oncol. 2015;27:94. 5
6 IC 50 (nm) Activity of First-, Second-, and Third-Generation EGFR TKIs Against EGFR Mutations T790M Wild-type Wild-type T790M 1 EGFRm Wild-type EGFRm EGFRm T790M Gefitinib Afatinib Osimertinib Wild-type EGFR T790M EGFR mutant: L858R, exon 19 del IC 50 = half-maximal inhibitory concentration. Li et al. Oncogene. 2008;27:4702; Cross et al. Cancer Discov. 2014;4:1046; Hirano et al. Oncotarget. 2015;6:
7 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 7
8 months First- and Second-Generation EGFR TKIs Are Standard for First-line Treatment of NSCLC With Common EGFR Mutations Better PFS vs platinum-based chemotherapy a a EURTAC ENSURE OPTIMAL WJTOG NJE002 IPASS LL3 LL6 EURTAC ENSURE OPTIMAL WJTOG NJE002 IPASS LL3 LL6 Erlotinib Gefitinib a Afatinib Platinum-based chemotherapy a PFS not reported for common mutations only. NSCLC = non small cell lung cancer. Chen et al. Ann Oncol. 2013;24:1615; Gefitinib Summary of Product Characteristics 2010; Han et al. J Clin Oncol. 2012;30:1122; Maemondo et al. N Engl J Med. 2010;362:2380; Mok et al. N Engl J Med. 2009;361:947; Mitsudomi et al. Lancet Oncol. 2010;11:121; Rosell et al. Lancet Oncol. 2012;13:239; Sequist et al. J Clin Oncol. 2013;31:3327; Wu et al. Lancet Oncol. 2014;15:213; Wu et al. Ann Oncol. 2015;26:1883; Zhou et al. Lancet Oncol. 2011;8:735. 8
9 First- and Second-Generation EGFR TKIs Are Not Equal: Response Rate and PFS in LUX-Lung 7 LUX-Lung 7: Afatinib vs Gefitinib Park et al. Lancet Oncol. 2016;17:577; Corral et al. ELCC Abstract 93PD. 9
10 First- and Second-Generation EGFR TKIs Are Not Equal: PFS in ARCHER 1050 ARCHER 1050: Dacomitinib vs Gefitinib (excluding CNS metastases) CNS = central nervous system; ITT = intent-to-treat; CI, confidence interval. Mok et al. ASCO Abstract LBA
11 First and Third-Generation EGFR TKIs Are Not Equal: PFS in FLAURA FLAURA: Osimertinib vs Gefitinib or Erlotinib 11 Ramalingam et al. ESMO Abstract LBA2.
12 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 12
13 Safety Second- or Third-Generation TKIs vs First-Generation TKIs LUX-Lung 7 1,2 ARCHER FLAURA 4 Afatinib (n=160) Gefitinib (n=159) Dacomitinib (n=227) Gefitinib (n=225) Osimertinib (n=279) Treatment discontinuation rate 6.3% 6.3% 9.7% 6.6% 13.0% (any) Most common grade 3 AEs Diarrhoea: 12% Rash/acne: 9% Liver enzyme elevation: 9% Rash/acne: 3% Acne: 14% Diarrhoea: 9% Paronychia: 8% Liver enzyme elevation: 9% Paronychia: 1% Diarrhoea: 2% Decreased appetite: 3% 1. Park et al. Lancet Oncol. 2016;17:577; 2. Paz-Ares et al. Ann Oncol. 2017;28:270; 3. Mok et al. ASCO Abstract LBA9007; 4. Ramalingam et al. ESMO Abstract LBA2. 13
14 Dose Reduction of Afatinib Reduced Drug-Related AEs Without Compromising Efficacy PFS = progression-free survival; HR = hazard ratio; CI = confidence interval. Hirsch V, et al. ASCO 2016 poster presentation:
15 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 15
16 DDIs of First-, Second-, and Third-Generation EGFR TKIs Enzymes Involved in the Metabolism of Oral EGFR TKIs Drug Metabolised by CYP Enzymes 3A4 3A5 2D6 1A1 1A2 1B1 2C8 2C9 May Inhibit May Induce Gefitinib Erlotinib CYP2C19 (w) CYP2D6 (w) UGT1A9, BRCP CYP3A4 (m) CYP2C8 (m) CYP1A1 (s) UGT1A1 (s) CYP1A1 CYP1A2 Afatinib Dacomitinib CYP2D6 (s) Osimertinib BCRP CYP3A4 CYP1A2 CYP2C DDI = drug-drug interaction; CYP = cytochrome P450 enzyme; BCRP = breast cancer resistance protein; UGT = UDP-glycosyltransferase. Cross et al. Cancer Discov. 2014;4:1046; Li et al. Oncogene. 2008;27:4702; Peters et al. Cancer Treat Rev. 2014;40:917; TAGRISSO Prescribing Information. March
17 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 17
18 OS With Afatinib in EGFR-Mutant NSCLC Common Mutations (del19/l858r) (n=307) a Only 6 patients in the afatinib arm were treated with osimertinib because of lack of availibility (trial recruitment was from August 2009 to February 2011). NSCLC = non small cell lung cancer. Yang et al. Lancet Oncol. 2015;16:
19 Molecular Mechanisms of Acquired Resistance to First-/Second-Generation EGFR TKIs Yu HA et al. Clin Cancer Res. 2013;19:
20 OS in Patients Treated With Third-Generation TKIs Subsequently in LUX-Lung 7 20%/17% who discontinued afatinib/gefitinib received third-generation TKIs (osimertinib, olmutinib, rociletinib) NE = not estimable. Corral et al. ELCC Abstract 93PD. 20
21 Treatment Sequences in EGFR-Mutant NSCLC After First-line EGFR TKI 1st-/2nd-generation TKI T790M + T790M - Osimertinib Chemotherapy Chemotherapy Except if molecular target 1st-/2nd-generation TKI Other MET/HER2 inhibitor Osimertinib Chemotherapy Except if molecular target NEED MATURE OS AND TREATMENT SEQUENCES FROM AURA3 and FLAURA (med PFS = 18.9 months) 21
22 Key Factors in First-line EGFR TKI Selection Sequence makes survival Not all TKIs are equal Drug-drug interactions Efficacy Adverse event profile 22
23 Questions?
EGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationMaximising Clinical Benefit from TKIs in the Treatment of Advanced NSCLC
Maximising Clinical Benefit from TKIs in the Treatment of Advanced NSCLC 2017 WCLC- PACIFICO Yokohama Convention Center 16 October, 2017 BI symposium Meeting Welcome and Introductions 2017 WCLC- PACIFICO
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationTKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad
TKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad Dra Pilar Lianes Barragan Consorcio Sanitario del Maresme (Barcelona) Indice Epidemiología TKI en primera línea Eficacia
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationOsimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Editorial : a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma Niki Karachaliou 1, Feliciano Barron Barron 2, Santiago Viteri 3, Miguel Angel Molina 4, Rafael
More informationManagement of EGFR-mutant NSCLC. Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center
Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center Disclosures Research Funding: Merck, Novartis, AstraZeneca, Millenium Consulting: AbbVie,
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationEGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI
EGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI 217 Conversations in Oncology in Shanghai, China Dr. Daniel SW Tan Division of Medical Oncology, National Cancer Centre
More informationKeywords Erlotinib EGFR mutations Non-small-cell lung cancer (NSCLC) First line Japanese patients Overall survival ORIGINAL ARTICLE
DOI 10.1007/s10147-016-1039-0 ORIGINAL ARTICLE Final overall survival in JO22903, a phase II, open label study of first line erlotinib for Japanese patients with EGFR mutation positive non small cell lung
More informationEpidermal growth factor receptor (EGFR) mutations are
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationPresented at the European Society of Medical Oncology (ESMO), Munich, Germany, October 2018
Effectiveness of afatinib in clinical practice first results of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC in Germany Wolfgang M. Brueckl 1 *, Eckart Laack 2, Martin
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationLung Cancer. Karen Reckamp, MD Medical Director, Clinical Research. Click to edit Master Presentation Date
Advances in Targeted Therapy for Lung Cancer Karen Reckamp, MD Medical Director, Clinical Research City of Hope Comprehensive Cancer Center Click to edit Master Presentation Date Disclosures Consultant
More informationPost-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report) Nobuyuki Yamamoto, 1 Toshihiro Nukiwa, 2 Yoichi Nakanishi,
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationGIOTRIF (AFATINIB*) For journalists outside the US/UK/Canada only 1. WHAT IS GIOTRIF (AFATINIB*)? 2. HOW DOES GIOTRIF (AFATINIB*) WORK?
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationSequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Scan the QR code for an electronic copy of the poster and supplementary material Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationProfilo di tossicita degli inibitori di EGFR
Dipartimento di Oncologia direttore dr. Gianpiero Fasola NSCLC EGFR mutato: quali opzioni terapeutiche? Profilo di tossicita degli inibitori di EGFR Padova 17 settembre 2105 Alessandro Follador TKis in
More informationManagement of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center Rogerio Lilenbaum, MD Yale Cancer Center/Smilow Cancer Hospital EGFR Mutation
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationCompeting CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7
Competing CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7 Diego Kaen, 1 James C.-H. Yang, 2 Yi-Long Wu, 3 Vera Hirsh, 4 Kenneth O Byrne,
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationS. Morin Ben Abdallah md* and V. Hirsh md* REVIEW ARTICLE ABSTRACT INTRODUCTION. Key Words tkis, afatinib
REVIEW ARTICLE AFATINIB IN EGFR ACTIVATING MUTATION POSITIVE ADVANCED NSCLC, Morin Ben Abdallah and Hirsh Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR
More informationLa sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica?
La sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica? GRUPPO A Luca Toschi (former Vanesa Gregorc) Who are oncogene
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationErlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies
RESEARCH ARTICLE For reprint orders, please contact: reprints@futuremedicine.com Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from
More informationORIGINAL ARTICLE. Received 4 August 2015; revised 16 November 2015; accepted 20 November Journal of Thoracic Oncology Vol. - No.
ORIGINAL ARTICLE First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationBest of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer
Best of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer Howard (Jack) West, M JackWestM@gmail.com @JackWestM Swedish Cancer Institute Seattle, WA Best of ASCO 2014 Seattle, WA Learning Objectives
More informationPAVING THE PATH TO PRECISION MEDICINE IN NSCLC
PAVING THE PATH TO PRECISION MEDICINE IN NSCLC Using Biomarkers to Determine Treatment Course Disclaimer This slide deck in its original and unaltered format is for educational purposes. All materials
More informationSpecial Thanks! 10/5/2018. Page 1
Disclaimer This slide deck in its original and unaltered format is for educational purposes. All materials contained herein reflect the views of the faculty, and not those of Creative Educational Concepts,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationUpdate on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
Review Editorial For reprint orders, please contact: reprints@futuremedicine.com Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer Jaafar
More informationIn the last decade, the emergence of targeted therapies has changed the treatment paradigm for non-small cell lung cancer (NSCLC).
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer Tu Nguyen-Ngoc, 1 Martin Reck, 2 Daniel SW Tan 3 and Solange Peters 1 1. Department of Medical Oncology, Centre Hospitalier
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationOsimertinib (AZD9291) a science-driven, collaborative approach
Annals of Oncology Advance Access published March 8, 2016 1 Osimertinib (AZD9291) a science-driven, collaborative approach to rapid drug design and development A. Yver Global Medicines Development, AstraZeneca,
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationIs advanced lung cancer becoming a chronic disease?
Is advanced lung cancer becoming a chronic disease? James Chung-Man HO ( 何重文 ) M.D. FRCP Associate Professor, The University of Hong Kong Honorary Consultant, Department of Medicine Specialist in Respiratory
More informationTechnology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer Technology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
More informationLung cancer is the leading cause of cancer related death
Original Article Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non Small-Cell Lung Cancer Jih-Hsiang Lee, MD,* Yu-Lin Lin, MD,* Wei-Hsun Hsu, MD,* Hsuan-Yu Chen, PhD, # Yeun-Chung
More informationDrug-drug interactions with oncolytics (in particular PPIs and TKIs)
Drug-drug interactions with oncolytics (in particular PPIs and TKIs) Prof. Ron Mathijssen, MD PhD Medical Oncologist/ Clinical Pharmacologist Erasmus MC Cancer Institute Rotterdam ICPAD Workshop November
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationFirst-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
REVIEW NONSMALL CELL LUNG CANCER First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Martin Sebastian 1, Alexander Schmittel 2 and Martin Reck 3 Affiliations:
More informationEGFR-MUTATED METASTATIC NSCLC:
EGFR-MUTATED METASTATIC NSCLC: Opening Remarks Suresh S. Ramalingam, MD Professor of Hematology and Medical Oncology Assistant Dean for Cancer Research Emory University School of Medicine Roberto C. Goizueta
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationAfatinib in advanced NSCLC: a profile of its use
Drugs Ther Perspect (2018) 34:89 98 https://doi.org/10.1007/s40267-018-0482-6 ADIS DRUG Q&A Afatinib in advanced NSCLC: a profile of its use Emma D. Deeks 1 Gillian M. Keating 1 Published online: 1 February
More information